AgomAb Therapeutics NVAGMB +0.85%14 EBIT per Share is $-0.42 as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,173 Biotechnology companies, AgomAb Therapeutics NV ranks worse than 90.71% on this metric.
AgomAb Therapeutics NV's EBIT per Share for the
three
months ended in Dec. 2025 was $-0.42.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.42.
During the past 3 years, the average EBIT per Share Growth Rate was -29.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for AgomAb Therapeutics NV's EBIT per Share or its related term are showing as below:
AGMB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -29.1 Med: -29.1 Max: -29.1
Current: -29.1
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of AgomAb Therapeutics NV was -29.10% per year. The lowest was -29.10% per year. And the median was -29.10% per year.
AGMB's 3-Year EBIT Growth Rate is ranked worse than 90.71% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs AGMB: -29.10
AgomAb Therapeutics NV (NAS:AGMB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
AgomAb Therapeutics NV EBIT per Share Related Terms
AgomAb Therapeutics NV EBIT per Share Historical Data
* Premium members only.
The historical data trend for AgomAb Therapeutics NV's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AgomAb Therapeutics NV (AGMB) has a EBIT per Share of $-0.42 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on AgomAb Therapeutics NV and its competitors. According to the industry distribution chart, AgomAb Therapeutics NV ranks #1064 out of 1173 companies in the Biotechnology industry, placing it in the top 90.7%.
Is AgomAb Therapeutics NV's EBIT per Share too high?
AgomAb Therapeutics NV's current EBIT per Share is $-0.42. Based on the distribution chart, AgomAb Therapeutics NV ranks #1064 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's EBIT per Share compare to DNA and ACRS?
According to the Biotechnology industry distribution chart, AgomAb Therapeutics NV ranks #1064 out of 1173 companies for EBIT per Share. This places AgomAb Therapeutics NV in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on AgomAb Therapeutics NV and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AgomAb Therapeutics NV's current EBIT per Share is $-0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current EBIT per Share of $-0.42. The current EBIT per Share is $-0.42. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current EBIT per Share is $-0.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score
Get the complete analysis for AGMB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGMB has been successfully added to your 